Patent foramen ovale (PFO) closure reduced the risk for recurrent ischemic stroke in most young and middle-aged adults with cryptogenic stroke but increased the risk for atrial fibrillation (AF) in a ...

Five-year results from the randomized REDUCE trial show a continued benefit of patent foramen ovale (PFO) closure compared with antiplatelet therapy alone for the prevention of cryptogenic stroke.

Patent foramen ovale (PFO) closure in conjunction with optimal medical therapy can reduce both the number of migraine days and the frequency of attacks compared with medicine alone, according to a new ...

Shown are Kaplan–Meier estimates in the intention-to-treat population. The inset shows the same data on an enlarged y axis. The incidence of serious adverse events was similar in the two trial groups, ...

Researchers found closure of patent foramen ovale could result in reduced monthly migraine days. Treatment with patent foramen ovale (PFO) closure could reduce the frequency of headaches and monthly ...

W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...

The Society for Cardiovascular Angiography & Interventions (SCAI) today released official guidelines for the management of patent foramen ovale (PFO). A multidisciplinary guideline panel formulated 13 ...

LAS VEGAS, NV (May 8, 2009) — A new device designed to close a common heart defect known as a patent foramen ovale (PFO) is safe and effective at 90-days follow up, according to a new study released ...

The presence of a residual shunt after patent foramen ovale (PFO) closure is associated with an increased risk for recurrent stroke or transient ischemic attack (TIA), according to a study published ...

ATLANTA -- Scenarios for patent foramen ovale (PFO) closure not covered by the pivotal trials were a key subject of guidelines released by the Society for Cardiovascular Angiography and Interventions ...